Exelixis | EXEL - Selling And Administration Expenses



Exelixis reported $134.86M in Selling and Administration Expenses for its fiscal quarter ending in July of 2025.


Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 123.66M 2.71M Jun/2025
Agios Pharmaceuticals USD 45.87M 4.34M Jun/2025
Amgen USD 1.69B 4M Jun/2025
AstraZeneca USD 5.01B 1.42B Jun/2025
Bayer EUR 3.55B 162M Jun/2025
BioMarin Pharmaceutical USD 232.28M 26.16M Jun/2025
Bristol-Myers Squibb USD 1.71B 129M Jun/2025
Cytokinetics USD 65.72M 8.35M Jun/2025
Eisai JPY 100.16B 6.34B Jun/2025
Eli Lilly USD 2.75B 390.8M Jun/2025
Exelixis USD 134.86M 2.32M Jul/2025
Genmab DKK 144M 18M Jun/2025
Glaxosmithkline GBP 2.09B 609M Jun/2025
Incyte USD 331.02M 5.33M Jun/2025
Ionis Pharmaceuticals USD 90.6M 14.6M Jun/2025
MacroGenics USD 9.3M 18.51M Jun/2025
Merck USD 2.63B 104M Jun/2025
Moderna USD 230M 18M Jun/2025
Neurocrine Biosciences USD 286.3M 9.8M Jun/2025
Novartis USD 3.44B 384M Jun/2025
Pfizer USD 3.42B 406M Jun/2025
Sanofi EUR 2.32B 1.08B Jun/2025
Takeda JPY 255.89B 39.98B Jun/2025
Ultragenyx Pharmaceutical USD 86.65M 1.15M Jun/2025
Xencor USD 15.11M 2.22M Jun/2025